Showing results (241-250 of 277) with videos related to
Sort By:
Pageof 28
Cancer Medicine|September 26, 2022
The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysisTakeshi Hatanaka, Atsushi Naganuma, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 26, 2022
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysisTakeshi Hatanaka, Atsushi Hiraoka, Toshifumi Tada, et al.Cancer Medicine|December 15, 2022
Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Hepatology International|September 8, 2022
Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumabTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Cancer Medicine|October 13, 2022
Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational studyTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Oncology|September 14, 2022
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 6, 2023
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysisTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Journal of Gastroenterology and Hepatology|January 6, 2025
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk ModelsTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Liver Cancer|August 21, 2023
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter AnalysisAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Journal of Gastroenterology and Hepatology|May 26, 2023
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinomaToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Pageof 28